{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022575","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.443290+00:00","generated_at":"2026-05-17T17:35:48.298008+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion","bullets":["Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.","6% interest per annum; maturity date August 5, 2026.","Conversion price is 60% of lowest trading price over prior 20 trading days.","Beneficial ownership limitation set at 4.99% (can be increased to 9.99% by holder).","Shares upon conversion are unregistered and subject to restrictive legend."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022575","json":"https://secwatch.observer/filing/0001641172-25-022575.json","markdown":"https://secwatch.observer/filing/0001641172-25-022575.md","text":"https://secwatch.observer/filing/0001641172-25-022575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000164117225022575/0001641172-25-022575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000164117225022575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:35:48.298008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}